CN103705446A - Polyene phosphatidyl choline injection, and preparation method thereof - Google Patents
Polyene phosphatidyl choline injection, and preparation method thereof Download PDFInfo
- Publication number
- CN103705446A CN103705446A CN201210391320.5A CN201210391320A CN103705446A CN 103705446 A CN103705446 A CN 103705446A CN 201210391320 A CN201210391320 A CN 201210391320A CN 103705446 A CN103705446 A CN 103705446A
- Authority
- CN
- China
- Prior art keywords
- polyene phosphatidylcholine
- content
- sodium
- injection liquid
- polyene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title claims abstract description 104
- 150000004291 polyenes Chemical class 0.000 title claims abstract description 98
- 238000002347 injection Methods 0.000 title claims abstract description 59
- 239000007924 injection Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract description 41
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract description 37
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical group C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract description 29
- 239000002904 solvent Substances 0.000 claims abstract description 22
- 239000003381 stabilizer Substances 0.000 claims abstract description 21
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000001954 sterilising effect Effects 0.000 claims abstract description 17
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 14
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 9
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004380 Cholic acid Substances 0.000 claims abstract description 8
- 229960002471 cholic acid Drugs 0.000 claims abstract description 8
- 235000019416 cholic acid Nutrition 0.000 claims abstract description 8
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 8
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 claims abstract description 7
- 229960002997 dehydrocholic acid Drugs 0.000 claims abstract description 7
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims abstract description 7
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 claims abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 78
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 60
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 50
- 239000007788 liquid Substances 0.000 claims description 49
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 20
- 239000007983 Tris buffer Substances 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 150000001413 amino acids Chemical group 0.000 claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 15
- 239000002151 riboflavin Substances 0.000 claims description 15
- 235000019192 riboflavin Nutrition 0.000 claims description 15
- 229950001574 riboflavin phosphate Drugs 0.000 claims description 15
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 claims description 14
- 229960002477 riboflavin Drugs 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 238000007689 inspection Methods 0.000 claims description 12
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims description 12
- 238000001179 sorption measurement Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000008215 water for injection Substances 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 108010001515 Galectin 4 Proteins 0.000 claims description 4
- 102100039556 Galectin-4 Human genes 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000003860 storage Methods 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229940099352 cholate Drugs 0.000 abstract 1
- 229960000281 trometamol Drugs 0.000 abstract 1
- 229940083608 sodium hydroxide Drugs 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 16
- 150000003904 phospholipids Chemical class 0.000 description 13
- 239000003610 charcoal Substances 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- QSHVAZMOLNGWSY-UHFFFAOYSA-N 3-butyl-4-methoxyphenol Chemical group CCCCC1=CC(O)=CC=C1OC QSHVAZMOLNGWSY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Chemical group 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Chemical group CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000011709 vitamin E Chemical group 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical group COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of medicinal preparation, and specifically relates to a polyene phosphatidyl choline injection, and a preparation method thereof. The polyene phosphatidyl choline injection comprises polyene phosphatidyl choline, a solubilizer, an antiseptic, and a stabilizing agent; the solubilizer is selected from deoxycholic acid, deoxysodium cholate, dehydrocholic acid, sodium dehydrocholate, cholic acid, or sodium cholate; and the stabilizing agent is selected from amino acid, or a sodium salt thereof, or trometamol. Compared with a control group without the stabilizing agent, stability of the polyene phosphatidyl choline injection after high temperature sterilization and long-term storage is increased significantly, formula and preparation method are both simple, and the polyene phosphatidyl choline injection is convenient for industrialized production.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, in particular to a kind of stable Polyene Phosphatidylcholine injection liquid and preparation method thereof.
Background technology
Polyene phosphatidylcholine is a kind of lecithin in high purity extracting from soybean phospholipid, contain a large amount of unsaturated fatty acids, be mainly linoleic acid (accounting for 70%), linolenic acid and oleic acid, owing to being rich in multiple unsaturated fatty acid, therefore be called polyene phosphatidylcholine.Polyene phosphatidylcholine is " essential " phospholipid that can not synthesize in human body, is a kind of liver plasma membrane protective agent, can treat multiple acute and chronic hepatic disease.All there is liver plasma membrane and cell mitochondrial ultrastructure damage and accompany phospholipid loss and Cellular respiration and the synthetic deficiency of energy in various hepatopathys, take supplemented with exogenous phospholipid, unsaturated phospholipid is introduced in liver plasma membrane structure, substitute endogenous saturated phospholipid, can make membrane fluidity and transmembrane transport system activity strengthen, impaired membrane structure is therefore recovered.Polyene phosphatidylcholine is the comparatively sure hepatic of current curative effect.At present, this medicine has capsule and two kinds of dosage forms of injection.
Polyene Phosphatidylcholine injection liquid is phospholipid medicine, the same with other phospholipid, there is heat-labile feature, phospholipid hydrolysis in various degree all can occur in high temperature sterilize process and longer-term storage process, cause thus three large problems: 1) content of principal agent polyene phosphatidylcholine declines; 2) generation of toxicant LYSO-PHOSPHATIDYLCHOLINE LYSOPC; 3) hydrolysis of phospholipid causes product pH value to decline.
In fact, phospholipid hydrolysis generates LYSO-PHOSPHATIDYLCHOLINE LYSOPC and free fatty is the main cause that causes product pH value to decline, and therefore, controlling phospholipid hydrolysis is to control the fundamental means that product pH reduces.Yet the control that phospholipid is hydrolyzed in high temperature or longer-term storage process is the difficult problem extensively existing in phospholipid medicament research and development.
For improving the stability of polyene phosphatidylcholine, changing injection dosage form into freeze-dried powder dosage form is a kind of effective means that are generally considered.Existing numerous researcheres are attempted, such as following Chinese patent or patent application: CN201010264516.9, CN200510030631.9, CN200610009780.1, CN200510094998.7, CN200510021089.0, CN200510057457.7, CN200510037429.9, CN200610003436.1, CN200510021636.5 etc.Yet, to compare with injection dosage form, longer, production cost of production cycle of lyophilized formulations obviously increases, and need to additionally add freeze drying protectant; In addition, lyophilized formulations needs to redissolve with solvent before clinical use, complex operation, and easily cause liquid medicine contamination.
Therefore, develop a kind of Polyene Phosphatidylcholine injection liquid of good stability, for reducing production costs, simplify production operation, guaranteeing the higher practical value of the equal tool of clinical drug safety.There is researcher to be devoted to the exploitation of Polyene Phosphatidylcholine injection liquid, for example Chinese patent application CN200510105183.4 discloses a kind of infusion solutions that improves polyene phosphatidylcholine stability, and its polyene phosphatidylcholine by recipe quantity, nutrient, vitamin, cosolvent, antioxidant, isotonic agent, antiseptic, active carbon and water for injection form; Chinese patent CN200710050223.9 discloses the Polyene Phosphatidylcholine injection liquid that a kind of clarity is good, stability is strong, its polyene phosphatidylcholine by recipe quantity, benzyl alcohol, glycocholic acid or cholic acid or tween 80, ethanol or propylene glycol or glycerol, sodium hydroxide or sodium carbonate, 2,6 ditertiary butyl p cresol, tertiary butyl-4-hydroxy methoxybenzene and vitamin E form.But above-mentioned injection formula is more complicated, brought the problem of aspects such as cost, safety and Quality Control, therefore still needing to study new prescription solves the unsettled technical problem of polyene phosphatidylcholine.
Summary of the invention
Unexpectedly, when applicant finds to add aminoacid or its sodium salt or Tris in Polyene Phosphatidylcholine injection liquid, can significantly improve the stability of polyene phosphatidylcholine in high temperature sterilize and long term storage process.
One aspect of the present invention is to provide a kind of Polyene Phosphatidylcholine injection liquid, it comprises polyene phosphatidylcholine, solubilizing agent, antiseptic and stabilizing agent, wherein said solubilizing agent is selected from deoxycholic acid, sodium deoxycholate, dehydrocholic acid, sodium dehydrocholate, cholic acid or sodium cholate, and wherein said stabilizing agent is selected from aminoacid or its sodium salt or Tris.
Solubilizing agent of the present invention is preferably deoxycholic acid or sodium deoxycholate, more preferably deoxycholic acid.
Antiseptic of the present invention is preferably benzyl alcohol.
Aminoacid of the present invention comprises nonprotein amino acid and gal4 amino acid.Preferably, aminoacid is gal4 amino acid, comprises one or more in alanine, arginine, agedoite, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine.More preferably, aminoacid of the present invention is glycine or arginine or their mixture.
Except said components, polyene phosphatidylcholine of the present invention also can comprise other pharmaceutically acceptable components.These components include but not limited to sodium chloride, sodium hydroxide, riboflavin, riboflavin sodium phosphate, vitamin E, Vitamin E acetate, vitamin C, sodium L-ascorbate-2-phosphate, BHA (butylated hydroxyarisol, tertiary butyl-4-hydroxy methoxybenzene, Butylated hydroxyanisole), BHT (2,6-di-tert-butyl-4-methy phenol, 2,6 ditertiary butyl p cresol), sodium sulfite, sodium sulfite, sodium pyrosulfite, EDTA (ethylenediaminetetraacetic acid), EDETATE SODIUM and Ethylenediaminetetraacetic Acid Calcium Salt.Optionally, can add one or more these components.
The content of each component of Polyene Phosphatidylcholine injection liquid of the present invention is restriction especially, and those skilled in the art can eligibly select according to the characteristic of quantity, each component etc.Should be appreciated that, selected certain content is preferred content, is not intended to illustrate that other content can not reach technique effect of the present invention.
In a preferred embodiment of the present invention, Polyene Phosphatidylcholine injection liquid comprises following component and content (weight portion): polyene phosphatidylcholine 220-275 part, solubilizing agent 120-200 part, antiseptic 30-60 part, stabilizing agent 1-40 part, wherein said solubilizing agent is selected from deoxycholic acid, sodium deoxycholate, dehydrocholic acid, sodium dehydrocholate, cholic acid or sodium cholate, and wherein said stabilizing agent refers to aminoacid or its sodium salt or Tris.Preferably, Polyene Phosphatidylcholine injection liquid comprises following component and content (weight portion): polyene phosphatidylcholine 220-275 part, deoxycholic acid or sodium deoxycholate 120-200 part, benzyl alcohol 30-60 part, aminoacid or Tris 1-40 part.More preferably, Polyene Phosphatidylcholine injection liquid comprises following component and content (weight portion): polyene phosphatidylcholine 220-275 part, deoxycholic acid 120-200 part, benzyl alcohol 30-60 part, glycine or arginine or Tris 1-40 part.
In another preferred embodiment of the present invention, Polyene Phosphatidylcholine injection liquid of the present invention comprises following component and content (weight portion): polyene phosphatidylcholine 220-250 part, solubilizing agent 125-175 part, antiseptic 40-50 part, stabilizing agent 10-30 part, wherein said solubilizing agent is selected from deoxycholic acid, sodium deoxycholate, dehydrocholic acid, sodium dehydrocholate, cholic acid or sodium cholate, and wherein said stabilizing agent refers to aminoacid or its sodium salt or Tris.Preferably, Polyene Phosphatidylcholine injection liquid comprises following component and content (weight portion): polyene phosphatidylcholine 220-250 part, deoxycholic acid or sodium deoxycholate 125-175 part, benzyl alcohol 40-50 part, aminoacid or Tris 10-30 part.More preferably, Polyene Phosphatidylcholine injection liquid comprises following component and content (weight portion): polyene phosphatidylcholine 220-250 part, deoxycholic acid 125-175 part, benzyl alcohol 40-50 part, glycine or arginine or Tris 10-30 part.
In the present invention again in another preferred embodiment, Polyene Phosphatidylcholine injection liquid of the present invention comprises following component and content (weight portion): polyene phosphatidylcholine 230-245 part, solubilizing agent 140-160 part, antiseptic 45-50 part, stabilizing agent 15-25 part, wherein said solubilizing agent is selected from deoxycholic acid, sodium deoxycholate, dehydrocholic acid, sodium dehydrocholate, cholic acid or sodium cholate, and wherein said stabilizing agent refers to aminoacid or its sodium salt or Tris.Preferably, Polyene Phosphatidylcholine injection liquid comprises following component and content (weight portion): polyene phosphatidylcholine 230-245 part, deoxycholic acid or sodium deoxycholate 140-160 part, benzyl alcohol 45-50 part, aminoacid or Tris 15-25 part.More preferably, Polyene Phosphatidylcholine injection liquid comprises following component and content (weight portion): polyene phosphatidylcholine 230-245 part, deoxycholic acid 140-160 part, benzyl alcohol 45-50 part, glycine or arginine or Tris 15-25 part.
In the present invention, go back in a preferred embodiment, Polyene Phosphatidylcholine injection liquid of the present invention comprises following component and content (weight portion): 232.5 parts of polyene phosphatidylcholine, solubilizing agent 140-160 part, antiseptic 45-50 part, stabilizing agent 15-25 part, wherein said solubilizing agent is selected from deoxycholic acid, sodium deoxycholate, dehydrocholic acid, sodium dehydrocholate, cholic acid or sodium cholate, and wherein said stabilizing agent refers to aminoacid or its sodium salt or Tris.Preferably, Polyene Phosphatidylcholine injection liquid comprises following component and content (weight portion): 232.5 parts of polyene phosphatidylcholine, deoxycholic acid or sodium deoxycholate 140-160 part, benzyl alcohol 45-50 part, aminoacid or Tris 15-25 part.More preferably, Polyene Phosphatidylcholine injection liquid comprises following component and content (weight portion): 232.5 parts of polyene phosphatidylcholine, deoxycholic acid 140-160 part, benzyl alcohol 45-50 part, glycine or arginine or Tris 15-25 part.
In yet another embodiment of the invention, Polyene Phosphatidylcholine injection liquid of the present invention is except comprising component mentioned above and content (weight portion), also comprise following component and content (weight portion): sodium chloride 6-25 part, preferably 8-20 part, more preferably 10-18 part; Riboflavin or riboflavin sodium phosphate (in riboflavin) 0.1-2 part, preferably 0.3-1 part, more preferably 0.35-0.6 part; Sodium hydroxide 11-30 part, preferably 11-25 part, more preferably 15-20 part.
Another aspect of the present invention provides a kind of preparation method of Polyene Phosphatidylcholine injection liquid, and it comprises the following steps:
(1) under nitrogen protection, in the water for injection of 60%～95% amount of preparation, add each component, stir, if desired suitably heating;
(2) to the activated carbon adsorption 15～30min that adds 0.01%～1% (by weight) in step (1) solution, carry out afterwards decarbonisation;
(3) if necessary, with sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 7.5～9.5;
(4) add water to amount of preparation;
(5) filter, in nitrogen, cover lower embedding, sterilizing, inspection is qualified, obtains.
Wherein each component in step (1) can add simultaneously, also can first add a part, and then add remaining ingredient.In addition, the addition sequence of each component is restriction especially not, for example, can add at first polyene phosphatidylcholine, also can finally add polyene phosphatidylcholine.Part component also can add after the de-charcoal of step (2).
Wherein also can first sterilizing in step (5), then embedding under nitrogen covers, in step (5), also can not carry out sterilization steps in addition.
In addition, should be appreciated that, part steps in the method can be exchanged, for example can be prepared by the order of (1), (3), (4), (2), (5), but be not limited in this kind of exchange mode, those skilled in the art can desirably select as the case may be.
Polyene Phosphatidylcholine injection liquid of the present invention is compared with not adding contrasting of stabilizing agent, and high temperature sterilize and longer-term storage rear stability all significantly increase, and prescription and technique all simpler, be convenient to suitability for industrialized production.
They the invention is not restricted to particular methodology as herein described, scheme and reagent, because can change.In addition, term used herein is only for describing the object of particular, not to be intended to limit the scope of the invention.Unless clearly indication in literary composition, otherwise wording " comprises " and " comprising " is open rather than enclosed by being read as
The specific embodiment
Below in conjunction with specific embodiment, the present invention is conducted further description, yet in the present invention, these and other embodiment only do not limit the scope of the invention for illustrating.Equally, the invention is not restricted to any concrete preferred embodiment described herein.It should be appreciated by those skilled in the art that the replacement that is equal to that the technology of the present invention feature is done, or improve accordingly, within still belonging to protection scope of the present invention.
Embodiment 1
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 232.5g, deoxycholic acid 150g, arginine 17.8g, sodium chloride 16g, benzyl alcohol 48.2g, sodium hydroxide 15g and riboflavin sodium phosphate 0.45g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
Embodiment 2
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 232.5g, deoxycholic acid 160g, arginine 19.6g, sodium chloride 18g, benzyl alcohol 50g, sodium hydroxide 16.3g and riboflavin sodium phosphate 0.60g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
Embodiment 3
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 232.5g, deoxycholic acid 140g, Tris 15g, sodium chloride 10g, benzyl alcohol 47.6g, sodium hydroxide 16.8g and riboflavin sodium phosphate 0.50g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
Embodiment 4
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 232.5g, deoxycholic acid 150g, glycine 25g, sodium chloride 16g, benzyl alcohol 45g, sodium hydroxide 20g and riboflavin sodium phosphate 0.35g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
Embodiment 5
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 232.5g, deoxycholic acid 140g, glycine 18.8g, sodium chloride 15g, benzyl alcohol 47.3g, sodium hydroxide 15.5g and riboflavin sodium phosphate 0.35g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
Embodiment 6
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 232.5g, deoxycholic acid 150g, Tris 15.6g, sodium chloride 16g, benzyl alcohol 48g, sodium hydroxide 16.3g and riboflavin sodium phosphate 0.45g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
Embodiment 7
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 220g, deoxycholic acid 120g, arginine 1g, sodium chloride 6g, benzyl alcohol 30g, sodium hydroxide 11g and riboflavin sodium phosphate 0.1g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
Embodiment 8
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 245g, deoxycholic acid 160g, Tris 25g, sodium chloride 18g, benzyl alcohol 50g, sodium hydroxide 20g and riboflavin sodium phosphate 0.60g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
Embodiment 9:
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 275g, deoxycholic acid 200g, arginine 40g, sodium chloride 25g, benzyl alcohol 60g, sodium hydroxide 30g and riboflavin sodium phosphate 2.0g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
Control Example
The preparation 5L Polyene Phosphatidylcholine injection liquid of take is example, under nitrogen protection, in the water for injection of 70% amount of preparation, add polyene phosphatidylcholine 232.5g, deoxycholic acid 150g, sodium chloride 16g, benzyl alcohol 48.2g, sodium hydroxide 15g and riboflavin sodium phosphate 0.45g (in riboflavin), stir; Add 0.1% activated carbon adsorption 30min, de-charcoal; With sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 9.0; Add water to amount of preparation; Filter, in nitrogen, cover lower subpackage embedding, 121 ℃ of sterilizing 12min, inspection is qualified, obtains.
The high-temperature heating stability of embodiment 10 Polyene Phosphatidylcholine injection liquids
According to the prescription in embodiment 1-9 and control Example and method, prepare 10 batches of Polyene Phosphatidylcholine injection liquids.By every batch of injection at 121 ℃ of sterilizing 12min, the relatively variation of polyene phosphatidylcholine (PPC) content, major impurity LYSO-PHOSPHATIDYLCHOLINE LYSOPC (LPC) content and pH before and after sterilizing, wherein PPC content and LPC content are all 100% calculating by PPC labelled amount 46.5mg/mL.
The long-time stability of embodiment 11 Polyene Phosphatidylcholine injection liquids
According to the prescription in embodiment 1-9 and control Example and method, prepare 10 batches of Polyene Phosphatidylcholine injection liquids.Every batch of injection is placed under 4 ℃ of conditions and is preserved, respectively at 0 month, March, June, JIUYUE, December sampling and measuring, the relatively variation of polyene phosphatidylcholine (PPC) content, major impurity lysophosphatide (LPC) content and pH value, wherein PPC content and LPC content are all 100% calculating by PPC labelled amount 46.5mg/mL.
Claims (10)
1. a Polyene Phosphatidylcholine injection liquid, it comprises polyene phosphatidylcholine, solubilizing agent, antiseptic and stabilizing agent, wherein said solubilizing agent is selected from deoxycholic acid, sodium deoxycholate, dehydrocholic acid, sodium dehydrocholate, cholic acid or sodium cholate, and wherein said stabilizing agent is selected from aminoacid or its sodium salt or Tris.
2. the Polyene Phosphatidylcholine injection liquid of claim 1, it comprises following component and content: polyene phosphatidylcholine 220-275 part, solubilizing agent 120-200 part, antiseptic 30-60 part, stabilizing agent 1-40 part, wherein content is weight portion.
3. the Polyene Phosphatidylcholine injection liquid of claim 2, it comprises following component and content: polyene phosphatidylcholine 220-250 part, solubilizing agent 125-175 part, antiseptic 40-50 part, stabilizing agent 10-30 part, wherein content is weight portion.
4. the Polyene Phosphatidylcholine injection liquid of claim 3, it comprises following component and content: polyene phosphatidylcholine 230-245 part, solubilizing agent 140-160 part, antiseptic 45-50 part, stabilizing agent 15-25 part, wherein content is weight portion.
5. the Polyene Phosphatidylcholine injection liquid of claim 4, it comprises following component and content: 232.5 parts of polyene phosphatidylcholine, solubilizing agent 140-160 part, antiseptic 45-50 part, stabilizing agent 15-25 part, wherein content is weight portion.
6. the Polyene Phosphatidylcholine injection liquid of any one in claim 1-5, it also comprises following component and content: sodium chloride 6-25 part, riboflavin or riboflavin sodium phosphate 0.1-2 part, sodium hydroxide 11-30 part, wherein content is weight portion, and wherein riboflavin phosphate sodium content is in riboflavin.
7. the Polyene Phosphatidylcholine injection liquid of any one in claim 1-6, wherein said solubilizing agent is selected from deoxycholic acid or sodium deoxycholate, and wherein said stabilizing agent is selected from gal4 amino acid or Tris, and wherein said antiseptic is selected from benzyl alcohol.
8. the Polyene Phosphatidylcholine injection liquid of claim 7, wherein said solubilizing agent is deoxycholic acid.
9. the Polyene Phosphatidylcholine injection liquid of claim 7, wherein said gal4 amino acid is selected from glycine or arginine or their mixture.
10. a method of preparing the Polyene Phosphatidylcholine injection liquid of any one in claim 1-9, it comprises the following steps:
(1) under nitrogen protection, in the water for injection of 60%～95% amount of preparation, add each component, stir, if desired suitably heating;
(2) to the activated carbon adsorption 15～30min that adds 0.01%～1% in step (1) solution, carry out afterwards decarbonisation, wherein active carbon content is weight portion;
(3) if necessary, with sodium hydroxide solution or dilute hydrochloric acid solution, regulate pH to 7.5～9.5;
(4) add water to amount of preparation;
(5) filter, in nitrogen, cover lower embedding, sterilizing, inspection is qualified, obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210391320.5A CN103705446A (en) | 2012-10-08 | 2012-10-08 | Polyene phosphatidyl choline injection, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210391320.5A CN103705446A (en) | 2012-10-08 | 2012-10-08 | Polyene phosphatidyl choline injection, and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103705446A true CN103705446A (en) | 2014-04-09 |
Family
ID=50399043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210391320.5A Pending CN103705446A (en) | 2012-10-08 | 2012-10-08 | Polyene phosphatidyl choline injection, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103705446A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105566381A (en) * | 2015-12-29 | 2016-05-11 | 成都普思生物科技股份有限公司 | Preparation method for phosphatidylcholine for injection |
| CN108653204A (en) * | 2018-08-01 | 2018-10-16 | 辽宁海思科制药有限公司 | A kind of Polyene Phosphatidylcholine injection liquid pharmaceutical composition and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1602878A (en) * | 2004-08-26 | 2005-04-06 | 北京瑞伊人科技发展有限公司 | Preparation process of polyene phosphatidylcholine injection |
| CN1895224A (en) * | 2006-06-26 | 2007-01-17 | 裴泽军 | Polyvinyl-phosphorylcholine elaioplast preparation and its making method |
| CN101095942A (en) * | 2006-06-30 | 2008-01-02 | 北京民海生物科技有限公司 | Formulation of the Exendin injection medicine containing stabilizing agent |
| CN102311501A (en) * | 2010-07-08 | 2012-01-11 | 天津药物研究院 | Fusion protein comprising GLP-1 (Glucagon-Like Peptide) or analog thereof and preparation method as well as application thereof |
| CN102342931A (en) * | 2010-07-29 | 2012-02-08 | 江苏恒瑞医药股份有限公司 | Injectable parenteral medicinal preparation of temozolomide and preparation method thereof |
| CN102697712A (en) * | 2012-05-29 | 2012-10-03 | 杭州澳亚生物技术有限公司 | Disodium adenosine triphosphate injection and preparation method thereof |
-
2012
- 2012-10-08 CN CN201210391320.5A patent/CN103705446A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1602878A (en) * | 2004-08-26 | 2005-04-06 | 北京瑞伊人科技发展有限公司 | Preparation process of polyene phosphatidylcholine injection |
| CN1895224A (en) * | 2006-06-26 | 2007-01-17 | 裴泽军 | Polyvinyl-phosphorylcholine elaioplast preparation and its making method |
| CN101095942A (en) * | 2006-06-30 | 2008-01-02 | 北京民海生物科技有限公司 | Formulation of the Exendin injection medicine containing stabilizing agent |
| CN102311501A (en) * | 2010-07-08 | 2012-01-11 | 天津药物研究院 | Fusion protein comprising GLP-1 (Glucagon-Like Peptide) or analog thereof and preparation method as well as application thereof |
| CN102342931A (en) * | 2010-07-29 | 2012-02-08 | 江苏恒瑞医药股份有限公司 | Injectable parenteral medicinal preparation of temozolomide and preparation method thereof |
| CN102697712A (en) * | 2012-05-29 | 2012-10-03 | 杭州澳亚生物技术有限公司 | Disodium adenosine triphosphate injection and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 罗明生等: "《药剂辅料大全》", 31 January 2006, 四川出版集团•四川科学技术出版社 * |
| 顾学裘: "《药物制剂注解》", 31 May 1983, 人民卫生出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105566381A (en) * | 2015-12-29 | 2016-05-11 | 成都普思生物科技股份有限公司 | Preparation method for phosphatidylcholine for injection |
| CN108653204A (en) * | 2018-08-01 | 2018-10-16 | 辽宁海思科制药有限公司 | A kind of Polyene Phosphatidylcholine injection liquid pharmaceutical composition and preparation method thereof |
| CN108653204B (en) * | 2018-08-01 | 2022-04-08 | 海思科制药(眉山)有限公司 | Polyene phosphatidyl choline injection pharmaceutical composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9636376B2 (en) | Stable compositions of peptide epoxy ketones | |
| AU2011227083B2 (en) | Stable bortezomib formulations | |
| ES2559818T5 (en) | Procedure for preparing a levothyroxine solution | |
| WO2013022783A3 (en) | Progesterone containing oral dosage forms and related methods | |
| CN104812392A (en) | A stabilized pemetrexed formulation | |
| WO2016166653A1 (en) | Stable liquid pharmaceutical compositions of bortezomib | |
| CN103830204A (en) | Soft capsule containing silybum marianum extract and preparation method of soft capsule | |
| WO2013151341A1 (en) | Injectable composition comprising phosphatidylcholine and method for preparing thereof | |
| US10314880B2 (en) | Composition comprising bortezomib | |
| CN102784382B (en) | Argatroban pharmaceutical composition, and preparation method and application thereof | |
| CN101455631A (en) | Meglumine cyclic adenosine injection and preparation technique thereof | |
| CN103705446A (en) | Polyene phosphatidyl choline injection, and preparation method thereof | |
| CN103110640B (en) | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection | |
| US10772895B2 (en) | Pharmaceutical composition | |
| CN109875982B (en) | Palonosetron transdermal patch and preparation method thereof | |
| CN104587452A (en) | Solution for preparing thymalfasin preparation and method for preparing thymalfasin preparation by virtue of solution | |
| CN104606209A (en) | Compound vitamin medicine composition for injection and preparation method of compound vitamin medicine composition | |
| CN102008461B (en) | A kind of ibuprofen drug composite for injection | |
| US20110217364A1 (en) | Conjugated suramin amino compounds for medical conditions | |
| CN102961397B (en) | Pharmaceutical composition of fat emulsion injection and compound amino acid injection | |
| CN102138925B (en) | Tigecycline composition and preparation method thereof | |
| CN106806376A (en) | The pharmaceutical composition of paracetamol and glycyrrhizic acid or its salt or derivatives thereof | |
| CN105395490B (en) | A kind of freeze-dried powder of sodium pharmaceutical composition containing dextral-rabeprazole and preparation method thereof | |
| WO2019130228A1 (en) | Stable liquid compositions of melphalan | |
| US20240325303A1 (en) | Ketorolac liquid composition, preparation method therefor, and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140409 |
|
| RJ01 | Rejection of invention patent application after publication |